• Search
  • Advanced Search

Editorial

November 30, 2023


Summarizing the Intentions and Outcomes of JUO 2023 Issue 3
Cheol Kwak
J Urol Oncol. 2023;21(3):181-182.

Invited Review

November 30, 2023


Influence of Body Composition on the Perioperative and Survival Outcomes of Renal Cell Carcinoma
Edouard H. Nicaise, Benjamin N. Schmeusser, Yash B. Shah, et al.
J Urol Oncol. 2023;21(3):183-199.

The purpose of this review is to provide an up-to-date understanding of the literature describing the impact of body composition on renal cell carcinoma (RCC) prognosis and outcomes. Although obesity...

Topic Article

November 30, 2023


Preoperative Renal Artery Embolization Before Radical Nephrectomy for Nonmetastatic Renal Cell Carcinoma: A Propensity Score Matched Analysis
Jin Noh, Sang Hun Song, Gyoohwan Jung, et al.
J Urol Oncol. 2023;21(3):200-207.

Purpose: This study investigated the effects of preoperative renal artery embolization (PRAE) before radical nephrectomy (RN) for advanced nonmetastatic renal cell carcinoma (RCC) on perioperative and oncologic outcomes. Materials and Methods:...

Invited Review

November 30, 2023


The Future of Adjuvant Therapy in Renal Cell Carcinoma: Recent Insights and Prospects
Hyerim Ha, Joo Han Lim
J Urol Oncol. 2023;21(3):208-216.

Renal cell carcinoma (RCC) remains a significant challenge in oncology, prompting thorough investigations into adjuvant treatments aimed at enhancing both survival and quality of life for patients. In this review,...

Invited Review

November 30, 2023


Role of Radiotherapy in Metastatic Renal Cell Carcinomas: An Evolutionary Journey in a Misunderstood Histological Type
Chan Woo Wee, Jaeho Cho
J Urol Oncol. 2023;21(3):217-227.

Renal cell carcinoma (RCC) has traditionally been considered one of the most radioresistant tumors based on in vitro and clinical studies that utilized a low biologically effective dose. However, recent...

Invited Review

November 30, 2023


Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023
Jiwoong Yu, Hyun Hwan Sung
J Urol Oncol. 2023;21(3):228-240.

Bacillus Calmette-Guérin (BCG)-unresponsive non–muscle-invasive bladder cancer (NMIBC) poses a significant clinical challenge, prompting a need for effective treatment options. Although radical cystectomy is a standard approach, it is burdened by...

Topic Article

November 30, 2023


Early Experience With Pembrolizumab in Bacillus Calmette-Guérin Unresponsive Non–Muscle-Invasive Bladder Cancer
Chung Un Lee, Wan Song, Minyong Kang, et al.
J Urol Oncol. 2023;21(3):241-248.

Purpose: Radical cystectomy (RC) is recommended for patients with non–muscle-invasive bladder cancer (NMIBC) who are unresponsive to intravesical bacillus Calmette-Guérin (BCG) instillation. However, RC is a very risky treatment, and...

Original Article

November 30, 2023


Clinical Outcomes of Patients With Variant Histology of Urothelial Carcinoma After Radical Cystectomy
Dan Bee Lee, Jae Yeon Kim, Yun Ha Lee, et al.
J Urol Oncol. 2023;21(3):249-256.

Purpose: The efficacy of standard chemotherapy or radical cystectomy in patients who have urothelial tumors with variant histology (VH) is very limited in terms of their prognosis. This study aimed...

Topic Article

November 30, 2023


Predictive Factors of Abiraterone Response in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
Jaeyoung Cho, Jungyo Suh, Dalsan You, et al.
J Urol Oncol. 2023;21(3):257-263.

Purpose: This study aimed to identify predictive factors for the response to abiraterone in patients with high-risk metastatic hormone-sensitive prostate cancer (mHSPC). Materials and Methods: This study analyzed the clinical characteristics...

Topic Article

November 30, 2023


Nonregional Lymph Node Metastasis as a Predictor of Early Progression When Using Androgen Receptor Targeting Agents in Patients With Metastatic Castration-Resistant Prostate Cancer Without Previous Chemotherapy
Sihyeon Kim, Beom Yong Rho, Dong Hyuk Kang, et al.
J Urol Oncol. 2023;21(3):264-270.

Purpose: In present, the use of androgen receptor targeting agents (ARTA) is one of the standard treatments for metastatic castration-resistant prostate cancer (mCRPC) without previous chemotherapy. However, some patients may...

Original Article

November 30, 2023


Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel
Tae Hwan Kim, Seol Ho Choo, Kang Hee Shim, et al.
J Urol Oncol. 2023;21(3):271-276.

Purpose: We propose a new potential marker of progression-free survival (PFS) called negative delta-prostate-specific antigen (PSA) time ratio (NDPSATR) and compare it with conventional PSA response, defined as PSA decline...

Erratum: Addition of the second author

November 30, 2023


Clinical Significance of Rab27a as a Urinary Biomarker in Patients With Bladder Cancer
Ja Yoon Ku, Md Nazmul Huda, Eu Chang Hwang, et al.
J Urol Oncol. 2023;21(3):277-277.
Current Issue
Volume 21(3); Nov 2023
Articles in E-pub version are posted online ahead of regular printed publication.

Journal of
Urologic Oncology

Print ISSN: 2951-603X
Online ISSN: 2982-7043

Editorial Office
Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine,
101 Daehak-ro, Jongno-gu, Seoul 03080, Korea
TEL: +82-2-2072-0817,   FAX: +82-2-742-4665   Email: journal@e-juo.org                

Copyright © The Korean Urological Oncology Society.

Developed in M2PI